Claris Bio Raises $118 Million for Pivotal CSB-001 Development
Claris Bio announced a $118 million Series B financing intended to advance CSB-001 through pivotal development for limbal stem-cell deficiency. The financing materially improves runway and execution capacity. However, the announcement does not disclose…
